27929-89-1

Basic information

• Product Name: N,N-diethyl-2-{[(9-hydroxy-9H-fluoren-9-yl)carbonyl]oxy}ethanaminium chloride
• Synonyms: 2-(Diethylamino)ethyl 9-hydroxy-9H-fluorene-9-carboxylate hydrochloride (1:1); 9H-fluorene-9-carboxylic acid, 9-hydroxy-, 2-(diethylamino)ethyl ester, hydrochloride (1:1)
• CAS NO: 27929-89-1
• Molecular Formula: C₂₀H₂₄ClNO₃
• Molecular Weight: 361.8625
• Mol File: 27929-89-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 420.7°C at 760 mmHg
• Flash Point: 208.2°C
• Vapor Pressure: 7.9E-08mmHg at 25°C
• CAS DataBase Reference: N,N-diethyl-2-{[(9-hydroxy-9H-fluoren-9-yl)carbonyl]oxy}ethanaminium chloride(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-diethyl-2-{[(9-hydroxy-9H-fluoren-9-yl)carbonyl]oxy}ethanaminium chloride(27929-89-1)
• EPA Substance Registry System: N,N-diethyl-2-{[(9-hydroxy-9H-fluoren-9-yl)carbonyl]oxy}ethanaminium chloride(27929-89-1)

Safety Data

• Hazardous Substances Data: 27929-89-1(Hazardous Substances Data)

Upstream product

• 467-69-6 9-hydroxy-9-fluorene carboxylic acid 
• 100-35-6 2-(diethylamino)ethyl chloride 

Relevant articles and documents

Synthesis and Pharmacological Activity of 2-(Diethylamino)Ethyl 9-Hydroxy-9H-Fluorene-9-Carboxylate Hydrochloride

New fluorenecarboxylic acid derivatives (structural analogs of amizil) were synthesized. A compound with low toxicity (LD50 = 45 ± 9.9 mg/kg) and antidepressant and antianxiety effects was identified. The central and peripheral muscarinic anticholinergic properties of 2-dimethylaminoethyl 9-hydroxyfluorene-9-carboxylate were studied using an arecoline tremor model. Apharmacological analysis showed that the new amizil structural analog exhibited pronounced central muscarinic anticholinergic activity and did not possess peripheral muscarinic anticholinergic effects. The advantages of the tested compound over amizil, amitriptyline that is widely used in the clinic, and the benzodiazepine tranquilizer diazepam were discussed. The results indicated that 2-diethylaminoethyl 9-hydroxyfluorene-9-carboxylate was promising for further development for the treatment of depressive and anxiety disorders.